Search details
1.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Article
in English
| MEDLINE | ID: mdl-37308971
2.
Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
Cancer Sci
; 111(6): 2116-2122, 2020 Jun.
Article
in English
| MEDLINE | ID: mdl-32297407
3.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(6): 781-794, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31097405
4.
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Br J Haematol
; 180(2): 224-235, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29193019
5.
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Eur J Haematol
; 99(3): 199-206, 2017 Sep.
Article
in English
| MEDLINE | ID: mdl-28504846
6.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet Oncol
; 17(3): 319-331, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26899778
7.
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Leukemia
; 35(6): 1722-1731, 2021 06.
Article
in English
| MEDLINE | ID: mdl-32895455
8.
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Leuk Lymphoma
; 61(8): 1850-1859, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32268815
Results
1 -
8
de 8
1
Next >
>>